Cardiff Oncology, Inc..
CRDF.US | Research and experimental development on natural sciences and engineering
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing therapies that leverage oncolytic viruses to treat various cancers. Their primary focus is on utilizing oncolytic viruses to selectively infect and destroy cancer cells while stimulating an immune response against...Show More
Better Health for All
30
Cardiff Oncology is a clinical-stage biotechnology company entirely focused on developing novel cancer therapies, with its lead asset, onvansertib, being evaluated for various cancers including metastatic colorectal cancer, pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer.
1
This dedication means its entire business is devoted to health improvement. As a clinical-stage company, it has no commercial products, therefore, it generates no revenue from products with negative health impacts.
2
The company actively invests in health innovation, with a $40 million offering in December 2024 specifically earmarked for funding clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer and for general corporate purposes.
3
Information about its clinical trials is made available on ClinicalTrials.gov and through the company's website, indicating transparency regarding its research activities.
4
The company conducts its clinical trials at multiple sites across the US, with eligibility criteria listed on ClinicalTrials.gov, suggesting adherence to ethical standards for clinical research.
5
Fair Money & Economic Opportunity
0
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies. The provided articles discuss its expanded access program for onvansertib and clinical trial findings. There is no evidence that the company engages in lending, insurance, or other financial services. Therefore, all KPIs related to fair money and economic opportunity are not applicable, as the company's core business lies outside the financial sector and it does not offer financial products or services to consumers.
Fair Pay & Worker Respect
0
The provided articles focus exclusively on Cardiff Oncology's financial performance, including cash and investments, operating expenses, net loss, and clinical trial data, as well as updates on clinical trials and patent information. No specific, concrete data points or information relevant to any of the 'Fair Pay & Worker Respect' KPIs, such as living wage coverage, CEO-median pay ratio, collective bargaining, safety incident rates, pay equity, worker engagement, turnover rates, insecure contract share, or health insurance coverage, are present. The articles also do not provide any verifiable information regarding labor violation incidents.
Fair Trade & Ethical Sourcing
0
The provided articles, including corporate presentations and industry news, do not contain any specific data points or metrics relevant to Fair Trade & Ethical Sourcing.
1
There is no information regarding fair-trade certifications, supply-chain audits, forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend for CRDF.US.
2
Honest & Fair Business
-40
Cardiff Oncology established an anonymous ethics and compliance hotline on January 1, 2016.
1
This hotline is operated by Lighthouse Services, Inc., and offers multiple reporting methods including phone, website, email, and fax.
2
The company states that personal information is kept confidential unless provided, and the Audit Committee oversees investigations.
3
Kind to Animals
-50
Cardiff Oncology, Inc. conducts preclinical animal trials to assess product characteristics, pharmacology, and toxicity, including long-term tests like reproductive toxicity and carcinogenicity.
1
The company uses in vitro studies, but these are confirmed by in vivo combination studies, indicating that non-animal assays cover early-stage screens but are not replacing animal tests for complex endpoints.
2
The company's animal testing policy involves preclinical laboratory and animal tests, which must comply with federal regulations and good laboratory practices.
3
The company uses between 50,000 and 100,000 animals annually in testing, based on the 2008 UK cancer research data where 96.8% of animals used were mice, and the company's focus on cancer research, without transparent reduction targets.
4
No War, No Weapons
0
No evidence available to assess Cardiff Oncology, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Cardiff Oncology, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence available to assess Cardiff Oncology, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Cardiff Oncology states it has not experienced material cybersecurity incidents in recent years.
1
The company uses industry-standard encryption for credit card transactions and standard security measures and authentication tools.
2
Its privacy policy outlines user rights to access, rectify, erase, restrict, and port data, and object to processing, indicating compliance with GDPR.
3
The company also notes compliance with FDA regulations related to patient information and SEC reporting of cybersecurity incidents.
4
Zero Waste & Sustainable Products
-20
Cardiff Oncology, Inc. achieved a 22% reduction in laboratory waste in 2023.
1
The company also invested $1.2 million in sustainable laboratory infrastructure in 2023.
2